This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (4)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Oncology  • Oncology, Other  • Pathology & Laboratory Medicine  • Alert me on articles by topic  Social Bookmarking   What's this?

Tracy Hampton, PhD

JAMA. 2003;290:2529-2533.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

More than 5 years ago, a New York Times article described stunning effects of angiogenesis inhibitors in eradicating cancerous tumors in mice, unleashing a media frenzy. But the agents have failed to perform as hoped in the clinic. More than 60 antiangiogenic agents are in clinical trials in the United States, and while they appear to be safe and well tolerated, positive therapeutic outcomes have been scarce.

But many scientists believe the approach—blocking endothelial cells from forming new blood vessels to bring oxygen and nutrients to tumors—has great therapeutic potential under the right conditions, and research is continuing full force. Even while clinical trials proceed, investigators are developing new angiogenesis inhibitors, improving delivery systems, and refining their understanding of the processes involved in angiogenesis, as was evident from a conference sponsored by the American Association for Cancer Research, held in Chicago last month.

Cancer researchers are . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?